Clinical Trials Logo
  1. Home
  2. Sepsis Syndrome
  3. NCT03472170

Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote. — LACTOPREM  

SEPSIS SYNDROME Clinical Trial

Official title:
Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.

Clinical Trial Summary

To evaluate the efficacy of enteral administration of bovine lactoferrin (bLf) in the reduction of probable late sepsis or microbiologically proven in preterm infants with birth weight ≤ 1500 gr and / or gestational age ≤ 32 weeks.

Clinical Trial Description

To date there are no published clinical data that jointly assess the impact of direct Lf supplementation on oxidative status, on biomarkers of systemic inflammation and on the microbiota of premature infants with or without sepsis. Clarification of these additional questions is essential for a better understanding of the benefits and implications of enteral administration of Lf in preterm infants. The enteral administration of lactoferrin reduces the incidence of late sepsis in preterm infants of very low birth weight (BMPN). Enteral supplementation with lactoferrin in NBWNS can have a beneficial effect on the systemic oxidative and inflammatory state, and may contribute to the creation of a healthy faecal microbiota. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03472170
Study type Interventional
Source Maimónides Biomedical Research Institute of Córdoba
Contact Antonio Miguel Luque Pineda
Phone 00 34 957 011 040
Email uicec@imibic.org
Status Recruiting
Phase N/A
Start date May 4, 2017
Completion date March 1, 2020
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04560842 - The Efficacy of High-flow Nasal Cannula Oxygen Therapy in Sepsis Patients N/A
Completed NCT04475081 - Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis Phase 3
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT03371680 - Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Enrolling by invitation NCT05602584 - Effect of Immunophenotype on Prognosis of Sepsis
Completed NCT06338111 - Interventions Meant to Improve the Outcome of Critical Care Patients in the ED
Completed NCT04292431 - Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT03956043 - Diagnostic Accuracy in Sepsis
Recruiting NCT05977153 - CT for Personalized Mechanical Ventilation N/A
Completed NCT00448968 - The Utility of Ischemia Modified Albumin (IMA) in Sepsis N/A
Completed NCT05246969 - Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Recruiting NCT05261607 - Analysis of the Evolution of Mortality in an Intensive Care Unit
Recruiting NCT04203979 - Sepsis: From Syndrome to Personalized Care
Recruiting NCT03990467 - Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU N/A
Recruiting NCT05338359 - Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis
Completed NCT02562261 - Platelet REactivity in Sepsis Syndrome (PRESS)
Active, not recruiting NCT02643121 - Utility of Presepsin in Children Sepsis N/A
Completed NCT00142220 - The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients Phase 4